Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
1.
Chonnam Medical Journal ; : 81-85, 2015.
Article de Anglais | WPRIM | ID: wpr-121246

RÉSUMÉ

The present study analyzed the prognostic impact of MET gene copy number in patients with curatively resected gastric cancer who received a combination regimen of cisplatin and S-1. The MET gene copy number was analyzed by use of quantitative real-time polymerase chain reaction. From January 2006 to July 2010, 70 tumor samples from 74 patients enrolled in a pilot study were analyzed. According to a cutoff MET gene copy number of > or =2 copies, a high MET gene copy number was observed in 38 patients (54.3%). The characteristics of the 2 groups divided according to MET gene copy number were similar. With a median follow-up duration of 26.4 months (range, 2.6-73.2 months), the estimated 3-year relapse-free survival and overall survival rates were 54.3% and 77.4%, respectively. No significant association was observed between the MET gene copy number and survival in a multivariate analysis. The MET gene copy number investigated in this study was not found to be associated with prognosis in patients with curatively resected gastric cancer.


Sujet(s)
Humains , Traitement médicamenteux adjuvant , Cisplatine , Études de suivi , Dosage génique , Analyse multifactorielle , Projets pilotes , Pronostic , Réaction de polymérisation en chaine en temps réel , Tumeurs de l'estomac , Taux de survie
2.
Chonnam Medical Journal ; : 81-85, 2015.
Article de Anglais | WPRIM | ID: wpr-788313

RÉSUMÉ

The present study analyzed the prognostic impact of MET gene copy number in patients with curatively resected gastric cancer who received a combination regimen of cisplatin and S-1. The MET gene copy number was analyzed by use of quantitative real-time polymerase chain reaction. From January 2006 to July 2010, 70 tumor samples from 74 patients enrolled in a pilot study were analyzed. According to a cutoff MET gene copy number of > or =2 copies, a high MET gene copy number was observed in 38 patients (54.3%). The characteristics of the 2 groups divided according to MET gene copy number were similar. With a median follow-up duration of 26.4 months (range, 2.6-73.2 months), the estimated 3-year relapse-free survival and overall survival rates were 54.3% and 77.4%, respectively. No significant association was observed between the MET gene copy number and survival in a multivariate analysis. The MET gene copy number investigated in this study was not found to be associated with prognosis in patients with curatively resected gastric cancer.


Sujet(s)
Humains , Traitement médicamenteux adjuvant , Cisplatine , Études de suivi , Dosage génique , Analyse multifactorielle , Projets pilotes , Pronostic , Réaction de polymérisation en chaine en temps réel , Tumeurs de l'estomac , Taux de survie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE